The Case For Hims & Hers: Diversification And Growth Beyond Semaglutide
Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Why Hims & Hers Health Inc (HIMS) Is Surging In 2025?
We recently published a list of Why These 15 Defensive Stocks Are Surging In 2025. In this article, we are going to take a ...
Zacks Investment Research on MSN4h
Hims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for Investors
The latest trading session saw Hims & Hers Health, Inc. (HIMS) ending at $37.04, denoting a -0.99% adjustment from its last day's close. This change lagged the S&P 500's daily gain of 0.16%. At the ...
Meta: My 3 Favorite Aspects Of The Thesis
Discover how Meta's India, WhatsApp, and AI businesses are poised to drive growth and boost cash flows, shaping the company's ...
Zacks Investment Research on MSN12h
ABT Stock to Gain From FDA IDE Approval for Its Coronary IVL System
Abbott ABT has received the FDA’s investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (“IVL”) system to evaluate the treatment of severe calcification in coronary ...
Health Care Cos. Slide Amid High-Risk Concerns — Health Care Roundup
Health care companies slid as traders retreated from high-risk issues. Shares of obesity-drug maker Novo Nordisk and Hims & Hers Health, the compounding pharmacy seeking to compete with the ...